» Articles » PMID: 39433296

Phosphorous Metabolism and Manipulation in Chronic Kidney Disease

Overview
Specialty Nephrology
Date 2024 Oct 21
PMID 39433296
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic kidney disease-mineral bone disorder (CKD-MBD) is a syndrome commonly observed in subjects with impaired renal function. Phosphate metabolism has been implicated in the pathogenesis of CKD-MBD and according to the phosphorocentric hypothesis may be the key player in the pathogenesis of these abnormalities. As phosphorous is an essential component for life, absorption from the bowel, accumulation and release from the bones, and elimination through the kidneys are all homeostatic mechanisms that maintain phosphate balance through very sophisticated feedback mechanisms, which comprise as main actors: vitamin D (VD), parathyroid hormone (PTH), calciproteins particles (CPPs), fibroblast growth factor-23 (FGF-23) and other phosphatonins and klotho. Indeed, as the renal function declines, factors such as FGF-23 and PTH prevent phosphate accumulation and hyperphosphatemia. However, these factors per se may be responsible for the organ damages associated with CKD-MBD, such as bone osteodystrophy and vascular calcification. We herein review the current understanding of the CKD-MBD focusing on phosphorous metabolism and the impact of phosphate manipulation on surrogate and hard outcomes.

Citing Articles

Editorial: Insights in cardiovascular and smooth muscle pharmacology: 2023.

Schildt S, Reichart D, Lebek S Front Pharmacol. 2025; 15():1544594.

PMID: 39834824 PMC: 11743381. DOI: 10.3389/fphar.2024.1544594.


Phosphorous metabolism and manipulation in chronic kidney disease.

Marando M, Tamburello A, Salera D, Di Lullo L, Bellasi A Nephrology (Carlton). 2024; 29(12):791-800.

PMID: 39433296 PMC: 11579558. DOI: 10.1111/nep.14407.

References
1.
Jamal S, Vandermeer B, Raggi P, Mendelssohn D, Chatterley T, Dorgan M . Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013; 382(9900):1268-77. DOI: 10.1016/S0140-6736(13)60897-1. View

2.
Coresh J, Selvin E, Stevens L, Manzi J, Kusek J, Eggers P . Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298(17):2038-47. DOI: 10.1001/jama.298.17.2038. View

3.
Pierides A, Edwards Jr W, Cullum Jr U, McCALL J, ELLIS H . Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness. Kidney Int. 1980; 18(1):115-24. DOI: 10.1038/ki.1980.117. View

4.
Block G, Rosenbaum D, Yan A, Greasley P, Chertow G, Wolf M . The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. Nephrol Dial Transplant. 2018; 34(2):339-346. PMC: 6365767. DOI: 10.1093/ndt/gfy061. View

5.
Bellasi A, Mandreoli M, Baldrati L, Corradini M, Di Nicolo P, Malmusi G . Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol. 2011; 6(4):883-91. PMC: 3069383. DOI: 10.2215/CJN.07810910. View